ResearcherUniversity Health NetworkActive in the last 2 years
Kai Duan
Matched on ORCID iD 0000-0002-3401-7228; OpenAlex author ID A5031077858. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 30
2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: 3 papers
Papers 4
- GATA6 immunohistochemistry and prognosis after surgical resection of pancreatic adenocarcinoma: results from the ESPAC-4 trial. First author DOI 10.1016/j.esmogo.2025.100138↗
- PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Panc… Co-author DOI 10.1200/jco-25-00436↗
- Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metast… Co-author DOI 10.1200/jco-25-02195↗
- The value of GATA6 immunohistochemistry and computer-assisted diagnosis to predict clinical outcome in advanced pancreatic cancer. Co-author DOI 10.1038/s41598-021-94544-3↗
Closest collaborators
The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Robert C. Grant · 4 shared papers, 2021–2025 · strength 0.65
- Paper GATA6 immunohistochemistry and prognosis after surgical resection of pancreatic adenocarcinoma: results from the ESPAC-… DOI 10.1016/j.esmogo.2025.100138↗
- Paper PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives … DOI 10.1200/jco-25-00436↗
- Paper Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Corr… DOI 10.1200/jco-25-02195↗
- Grainne Mary O'Kane · 4 shared papers, 2021–2025 · strength 0.65
- Paper GATA6 immunohistochemistry and prognosis after surgical resection of pancreatic adenocarcinoma: results from the ESPAC-… DOI 10.1016/j.esmogo.2025.100138↗
- Paper PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives … DOI 10.1200/jco-25-00436↗
- Paper Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Corr… DOI 10.1200/jco-25-02195↗
- Steve Gallinger · 4 shared papers, 2021–2025 · strength 0.65
- Paper GATA6 immunohistochemistry and prognosis after surgical resection of pancreatic adenocarcinoma: results from the ESPAC-… DOI 10.1016/j.esmogo.2025.100138↗
- Paper PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives … DOI 10.1200/jco-25-00436↗
- Paper Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Corr… DOI 10.1200/jco-25-02195↗
- Faiyaz Notta · 4 shared papers, 2021–2025 · strength 0.65
- Paper GATA6 immunohistochemistry and prognosis after surgical resection of pancreatic adenocarcinoma: results from the ESPAC-… DOI 10.1016/j.esmogo.2025.100138↗
- Paper PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives … DOI 10.1200/jco-25-00436↗
- Paper Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Corr… DOI 10.1200/jco-25-02195↗
- Sandra Elisabeth Fischer · 3 shared papers, 2021–2025 · strength 0.46
- Paper PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives … DOI 10.1200/jco-25-00436↗
- Paper Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Corr… DOI 10.1200/jco-25-02195↗
- Paper The value of GATA6 immunohistochemistry and computer-assisted diagnosis to predict clinical outcome in advanced pancrea… DOI 10.1038/s41598-021-94544-3↗
- Jennifer Jane Knox · 3 shared papers, 2021–2025 · strength 0.46
- Paper PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives … DOI 10.1200/jco-25-00436↗
- Paper Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Corr… DOI 10.1200/jco-25-02195↗
- Paper The value of GATA6 immunohistochemistry and computer-assisted diagnosis to predict clinical outcome in advanced pancrea… DOI 10.1038/s41598-021-94544-3↗
- Harshabad Singh · 2 shared papers, 2025 · strength 0.33
- Paper PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives … DOI 10.1200/jco-25-00436↗
- Paper Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Corr… DOI 10.1200/jco-25-02195↗
- Craig Devoe · 2 shared papers, 2025 · strength 0.33
- Paper PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives … DOI 10.1200/jco-25-00436↗
- Paper Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Corr… DOI 10.1200/jco-25-02195↗
- Eileen Mary O'Reilly · 2 shared papers, 2025 · strength 0.33
- Paper PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives … DOI 10.1200/jco-25-00436↗
- Paper Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Corr… DOI 10.1200/jco-25-02195↗
- Fieke E. M. Froeling · 2 shared papers, 2025 · strength 0.33
- Paper PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives … DOI 10.1200/jco-25-00436↗
- Paper Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Corr… DOI 10.1200/jco-25-02195↗
- Raymond Jang · 2 shared papers, 2025 · strength 0.33
- Paper PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives … DOI 10.1200/jco-25-00436↗
- Paper Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Corr… DOI 10.1200/jco-25-02195↗
- Daniel A. King · 2 shared papers, 2025 · strength 0.33
- Paper PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives … DOI 10.1200/jco-25-00436↗
- Paper Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Corr… DOI 10.1200/jco-25-02195↗
- Andrew J. Aguirre · 2 shared papers, 2025 · strength 0.33
- Paper PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives … DOI 10.1200/jco-25-00436↗
- Paper Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Corr… DOI 10.1200/jco-25-02195↗
- Elizabeth M. Jaffee · 2 shared papers, 2025 · strength 0.33
- Paper PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives … DOI 10.1200/jco-25-00436↗
- Paper Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Corr… DOI 10.1200/jco-25-02195↗
- Brian Matthew Wolpin · 2 shared papers, 2025 · strength 0.33
- Paper PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives … DOI 10.1200/jco-25-00436↗
- Paper Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Corr… DOI 10.1200/jco-25-02195↗
- Daniel John Renouf · 2 shared papers, 2025 · strength 0.33
- Paper PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives … DOI 10.1200/jco-25-00436↗
- Paper Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Corr… DOI 10.1200/jco-25-02195↗
- Erica S. Tsang · 2 shared papers, 2025 · strength 0.33
- Paper PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives … DOI 10.1200/jco-25-00436↗
- Paper Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Corr… DOI 10.1200/jco-25-02195↗
- Kimberly J. Perez · 2 shared papers, 2025 · strength 0.33
- Paper PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives … DOI 10.1200/jco-25-00436↗
- Paper Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Corr… DOI 10.1200/jco-25-02195↗
- Michael Jon Pishvaian · 2 shared papers, 2025 · strength 0.33
- Paper PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives … DOI 10.1200/jco-25-00436↗
- Paper Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Corr… DOI 10.1200/jco-25-02195↗
- David Arthur Tuveson · 2 shared papers, 2025 · strength 0.33
- Paper PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives … DOI 10.1200/jco-25-00436↗
- Paper Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Corr… DOI 10.1200/jco-25-02195↗
- Kenneth H. Yu · 2 shared papers, 2025 · strength 0.33
- Paper PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives … DOI 10.1200/jco-25-00436↗
- Paper Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Corr… DOI 10.1200/jco-25-02195↗
- Daniel A. Laheru · 2 shared papers, 2025 · strength 0.33
- Paper PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives … DOI 10.1200/jco-25-00436↗
- Paper Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Corr… DOI 10.1200/jco-25-02195↗
- Sven Fischer · 1 shared paper, 2025 · strength 0.19
- Paula Ghaneh · 1 shared paper, 2025 · strength 0.19
- Markus Wolfgang Büchler · 1 shared paper, 2025 · strength 0.19
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.